Co-Diagnostics, Inc.
CODXHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeCo-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in. Valued at $3.8M, CODX is a micro-cap name in its sector. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
Market Cap
$3.8M
Beta
2.90
P/E (TTM)
—
P/E (Fwd)
-0.66
EPS (TTM)
$-26.14
EPS (Fwd)
$-0.83
ROE
-174.8%
ROA
-59.6%
Cash
$3.6M
Total Debt
$1.8M
Free CF
-$17.5M
52W Change
-98.6%
Annual Financials
Cash vs Debt
Where CODX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CODX finished 69.55% below its 150-day moving average ($2.20) and 72.20% below its 200-day moving average ($2.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CODX overbought or oversold?
At the October 20, 2026 close, CODX's RSI(14) was 27.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Co-Diagnostics, Inc. holds $3.6M in cash against $1.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$17.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -174.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $97.9M (2021) to $622K (2025), a 99% decline worth watching.
With a beta above 1.5, CODX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CODX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Co-Diagnostics, Inc.'s trajectory.